Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus

Journal of Virology

Volumn 87, Issue 9, 2013, Pages 4952-4964

  Herbert, Andrew S ^a   Kuehne, Ana I ^a   Barth, James F ^a   Ortiz, Ramon A ^a   Nichols, Donald K ^a   Zak, Samantha E ^a   Stonier, Spencer W ^a   Muhammad, Majidat A ^a   Bakken, Russell R ^a   Prugar, Laura I ^a   Olinger, Gene G ^a   Groebner, Jennifer L ^a,c   Lee, John S ^a,d   Pratt, William D ^a   Custer, Max ^b,e   Kamrud, Kurt I ^b,f   Smith, Jonathan F ^b,g   Hart, Mary Kate ^a,h   Dye, John M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b AlphaVax Inc   (United States)

^c CATHOLIC UNIVERSITY OF AMERICA   (United States)

^d Military Infectious Diseases Research Program   (United States)

^e Novartis Vaccines and Diagnostics   (United States)

^f Harrisvaccines Inc   (United States)

^g PaxVax Inc   (United States)

^h A CSC Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLAVIRUS VACCINE; GLYCOPROTEIN; UNCLASSIFIED DRUG; VENEZUELAN EQUINE ENCEPHALITIS VIRUS REPLICON PARTICLE VACCINE; VIRUS VACCINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FILOVIRIDAE; IMMUNE RESPONSE; INFECTION PREVENTION; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; SINGLE DRUG DOSE; SUDAN VIRUS; SURVIVAL RATE; VACCINATION; VACCINE PRODUCTION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; EBOLAVIRUS; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACACA FASCICULARIS; REPLICON; VACCINATION; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS; MACACA; PRIMATES; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 84876306476     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03361-12     Document Type: Article

References (49)

1. Hoenen T, Groseth A, Falzarano D, Feldmann H. 2006. Ebola virus:unraveling pathogenesis to combat a deadly disease. Trends Mol. Med. 12:206-215
2. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchkov VE, Jahrling PB. 2010. Proposal for a revised taxonomy of the family Filoviridae:classification, names of taxa and viruses, and virus abbreviations. Arch. Virol. 155:2083-2103
3. Ascenzi P, Bocedi A, Heptonstall J, Capobianchi MR, Di Caro A, Mastrangelo E, Bolognesi M, Ippolito G. 2008. Ebolavirus and Marburgvirus:insight the Filoviridae family. Mol. Aspects Med. 29:151-185
4. Sanchez A, Feldmann GTWH. 2007. Filoviridae:Marburg and Ebola viruses, p 1409-1448. In Knipe DM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol 1. Lippincott/ Williams & Wilkins Co, Philadelphia, PA.
5. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Delicat A, Paweska JT, Gonzalez JP, Swanepoel R. 2005. Fruit bats as reservoirs of Ebola virus. Nature 438:575-576
6. Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, Rollin PE, Zaki SR, Peters CJ. 1996. Experimental inoculation of plants and animals with Ebola virus. Emerg. Infect. Dis. 2:321-325
7. Swanepoel R, Smit SB, Rollin PE, Formenty P, Leman PA, Kemp A, Burt FJ, Grobbelaar AA, Croft J, Bausch DG, Zeller H, Leirs H, Braack LE, Libande ML, Zaki S, Nichol ST, Ksiazek TG, Paweska JT. 2007. Studies of reservoir hosts for Marburg virus. Emerg. Infect. Dis. 13:1847-1851
8. Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, Kemp A, Swanepoel R, Paddock CD, Balinandi S, Khristova ML, Formenty PB, Albarino CG, Miller DM, Reed ZD, Kayiwa JT, Mills JN, Cannon DL, Greer PW, Byaruhanga E, Farnon EC, Atimnedi P, Okware S, Katongole-Mbidde E, Downing R, Tappero JW, Zaki SR, Ksiazek TG, Nichol ST, Rollin PE. 2009. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 5:e1000536. doi:10.1371/journal.ppat.1000536.
9. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ, Formenty P. 2009. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis. 9:723-728
10. Bermejo M, Rodriguez-Teijeiro JD, Illera G, Barroso A, Vila C, Walsh PD. 2006. Ebola outbreak killed 5000 gorillas. Science 314:1564.
11. Walsh PD, Breuer T, Sanz C, Morgan D, Doran-Sheehy D. 2007. Potential for Ebola transmission between gorilla and chimpanzee social groups. Am. Nat. 169:684-689
12. Johnson E, Jaax N, White J, Jahrling P. 1995. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76:227-236
13. Lub M, Sergeev AN, P'Iankov VO, P'Iankova GO, Petrishchenko VA, Kotliarov LA. 1995. Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route. Vopr. Virusol. 40:158-161
14. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM, Jr, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K. 2002. Hemorrhagic fever viruses as biological weapons:medical and public health management. JAMA 287:2391-2405
15. Reed DS, Mohamadzadeh M. 2007. Status and challenges of filovirus vaccines. Vaccine 25:1923-1934
16. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. 2011. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477:340-343
17. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. 2005. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645
18. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H. 2009. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 83:7296-7304
19. Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY. 2010. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin. Vaccine Immunol. 17:572-581
20. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, Stroher U, Fritz EA, Hensley LE, Jones SM, Feldmann H. 2008. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26:6894-6900
21. Falzarano D, Geisbert TW, Feldmann H. 2011. Progress in filovirus vaccine development:evaluating the potential for clinical use. Expert Rev. Vaccines 10:63-77
22. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus:expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 239:389-401
23. Schlesinger S. 2001. Alphavirus vectors:development and potential therapeutic applications. Expert Opin. Biol. Ther. 1:177-191
24. Davis NL, Brown KW, Johnston RE. 1996. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70:3781-3787
25. Frolov I, Frolova E, Schlesinger S. 1997. Sindbis virus replicons and Sindbis virus:assembly of chimeras and of particles deficient in virus RNA. J. Virol. 71:2819-2829
26. Smerdou C, Liljestrom P. 1999. Two-helper RNA system for production of recombinant Semliki Forest virus particles. J. Virol. 73:1092-1098
27. Rayner JO, Dryga SA, Kamrud KI. 2002. Alphavirus vectors and vaccination. Rev. Med. Virol. 12:279-296
28. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. 2000. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19:142-153
29. Wilson JA, Bray M, Bakken R, Hart MK. 2001. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 286:384-390
30. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. 1998. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251:28-37
31. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. 2002. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8:503-507
32. Kamrud KI, Alterson KD, Andrews C, Copp LO, Lewis WC, Hubby B, Patel D, Rayner JO, Talarico T, Smith JF. 2008. Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats. PLoS One 3:e2709. doi:10.1371/journal.pone.0002709.
33. Kamrud KI, Custer M, Dudek JM, Owens G, Alterson KD, Lee JS, Groebner JL, Smith JF. 2007. Alphavirus replicon approach to promoterless analysis of IRES elements. Virology. 360:376-387
34. Montgomery SA, Berglund P, Beard CW, Johnston RE. 2006. Ribosomal protein S6 associates with alphavirus nonstructural protein 2 and mediates expression from alphavirus messages. J. Virol. 80:7729-7739
35. Reap EA, Morris J, Dryga SA, Maughan M, Talarico T, Esch RE, Negri S, Burnett B, Graham A, Olmsted RA, Chulay JD. 2007. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25:7441-7449
36. Hartings JM, Roy CJ. 2004. The automated bioaerosol exposure system:preclinical platform development and a respiratory dosimetry application with nonhuman primates. J. Pharmacol. Toxicol. Methods. 49:39-55
37. Roy CJ, Pitt LM. 2006. Infectious disease aerobiology:aerosol challenge methods, p 61-76. In Swearengen JR (ed), Biodefense:research methodology and animal models. Taylor & Francis Group, Boca Raton, FL.
38. Moe JB, Lambert RD, Lupton HW. 1981. Plaque assay for Ebola virus. J. Clin. Microbiol. 13:791-793
39. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. 2012. Post-exposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. U. S. A. 109:5034-5039
40. Trombley AR, Wachter L, Garrison J, Buckley-Beason VA, Jahrling J, Hensley LE, Schoepp RJ, Norwood DA, Goba A, Fair JN, Kulesh DA. Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am. J. Trop. Med. Hyg. 82:954-960.
41. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11:786-790
42. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 424:681-684
43. Nishimoto KP, Laust AK, Wang K, Kamrud KI, Hubby B, Smith JF, Nelson EL. 2007. Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol. 20:88-104
44. + T cell responses to co-delivered antigen. Vaccine. 26:4267-4275
45. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. 1996. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. U. S. A. 93:3602-3607
46. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ. 2010. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog. 6:e1000904. doi:10.1371/journal.ppat .1000904.
47. Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, Strong JE, Marzi A, Takada A, Jones S, Gren J, Geisbert J, Jones SM, Geisbert TW, Feldmann H. 2011. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J. Infect. Dis. 204(Suppl 3):S1082-S1089.
48. Weaver SC. 2005. Host range, amplification, and arboviral disease emergence. Arch. Virol. 2005(Suppl):33-44.
49. Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC. 2004. Venezuelan equine encephalitis. Annu. Rev. Entomol. 49:141-174